[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100509829":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":48,"collaborators":10,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Prokidney","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CKD patients previously treated with REACT",null,"Participants Exposed to Renal Autologous Cell Therapy from studies RMCL-002, REGEN-003, REGEN-004 (REGEN-008S1).",[13],"Biological: Renal Autologous Cell Therapy (REACT)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"BIOLOGICAL","Renal Autologous Cell Therapy (REACT)","No interventions in this trial",[9],[21],{"name":22,"affiliation":5,"role":23},"Study Director","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Beth Hilburger","CONTACT","336-999-7031","info@prokidney.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Boise Kidney & Hypertension Institute","RECRUITING","Meridian","Idaho","83642","United States",{"type":39,"coordinates":40},"Point",[41,42],-116.39151,43.61211,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":10,"phoneExt":10,"email":10},"Arnold Silva, MD","PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100509829",false,"NCT05918523","A Long-Term Follow-Up Study of Participants Exposed to REACT","A Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy From Studies RMCL-002, REGEN-003, REGEN-004","Inclusion Criteria:\n\n* The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.\n\nExclusion Criteria:\n\n* The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.","ALL","30 Years","80 Years",{"count":60,"type":61},80,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).",[65,66],"Diabetic Kidney Disease","Chronic Kidney Diseases",[68,69,70],"REACT","DKD","CKD","2025-05-27",{"date":73,"type":74},"2025-05-28","ACTUAL",{"date":76,"type":74},"2023-12-11",{"date":78,"type":61},"2028-03",{"name":5,"class":6},1]